Methylation of TFPI 2 in Stool DNA : A Potential Novel Biomarker for the Detection of Colorectal Cancer

We have used a gene expression array–based strategy to identify the methylation of tissue factor pathway inhibitor 2 (TFPI2), a potential tumor suppressor gene, as a frequent event in human colorectal cancers (CRC). TFPI2 belongs to the recently described group of embryonic cell Polycomb group (PcG)–marked genes that may be predisposed to aberrant DNA methylation in early stages of colorectal carcinogenesis. Aberrant methylation of TFPI2 was detected in almost all CRC adenomas (97%, n = 56) and stages I to IV CRCs (99%, n = 115). We further explored the potential of TFPI2 as a biomarker for the early detection of CRC using stool DNA–based assays in patients with nonmetastatic CRC and average-risk noncancer controls who were candidates for screening. TFPI2 methylation was detected in stool DNA from stage I to III CRC patients with a sensitivity of 76% to 89% and a specificity of 79% to 93%. Detection of TFPI2 methylation in stool DNA may act as a useful adjunct to the noninvasive strategies for screening of CRCs in the future. [Cancer Res 2009;69(11):4691–9]

[1]  J. Stockman.  Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2010 .

[2]  S. Goodman,et al.  Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. , 2008, Gastroenterology.

[3]  Wim Van Criekinge,et al.  Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. , 2008, Cancer research.

[4]  Holly Janes,et al.  Practice of Epidemiology Adjusting for Covariates in Studies of Diagnostic, Screening, or Prognostic Markers: an Old Concept in a New Setting , 2022 .

[5]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[6]  C. Moon,et al.  The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth , 2008, Oncogene.

[7]  Dao-rong Wang,et al.  Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. , 2008, World journal of gastroenterology.

[8]  延山 嘉眞.  Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas , 2008 .

[9]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[10]  H. Hermeking,et al.  DNA Stool Test for Colorectal Cancer: Hypermethylation of the Secreted Frizzled-Related Protein-1 Gene , 2007, Diseases of the colon and rectum.

[11]  T. Mikkelsen,et al.  Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.

[12]  Wei Chen,et al.  Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer , 2007, PLoS genetics.

[13]  H. Fiegl,et al.  SFRP2 methylation in fecal DNA—a marker for colorectal polyps , 2007, International Journal of Colorectal Disease.

[14]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[15]  S. Baylin,et al.  Stem Cell Chromatin Patterns: An Instructive Mechanism for DNA Hypermethylation? , 2007, Cell cycle.

[16]  I. Ng,et al.  Tissue factor pathway inhibitor‐2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma , 2007, Hepatology.

[17]  Zhaohui Huang,et al.  Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions , 2007, Digestive Diseases and Sciences.

[18]  A. Saftoiu,et al.  Noninvasive detection through REMS-PCR technique of K-ras mutations in stool DNA of patients with colorectal cancer. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[19]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[20]  P. Laird,et al.  Epigenetic stem cell signature in cancer , 2007, Nature Genetics.

[21]  J. Minna,et al.  DNA methylation in health, disease, and cancer. , 2007, Current molecular medicine.

[22]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[23]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[24]  W. Gerald,et al.  A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies , 2006, PLoS medicine.

[25]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[26]  Kristian Helin,et al.  Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. , 2006, Genes & development.

[27]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[28]  D. Heresbach,et al.  Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test , 2006, European journal of gastroenterology & hepatology.

[29]  Nancy Breen,et al.  Patterns of Colorectal Cancer Screening Uptake among Men and Women in the United States , 2006, Cancer Epidemiology Biomarkers & Prevention.

[30]  G. Geiss,et al.  Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[31]  L. Myeroff,et al.  Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. , 2005, Journal of the National Cancer Institute.

[32]  M. Washington,et al.  Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  E. Lemarié,et al.  Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer , 2005, British Journal of Cancer.

[34]  Y. Miyagi,et al.  Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma , 2005, Oncogene.

[35]  D. Ahlquist,et al.  Stool screening for colorectal cancer: molecular approaches. , 2005, Gastroenterology.

[36]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[37]  M. Widschwendter,et al.  Methylation changes in faecal DNA: a marker for colorectal cancer screening? , 2004, The Lancet.

[38]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[39]  R Alexandra Goldbohm,et al.  Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. , 2003, Cancer research.